Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06342908 · ClinicalTrials.gov registry record · Phase 1
A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma
A Phase 1 study of Diffuse Hemispheric Glioma, H3 G34-Mutant, sponsored by Jonsson Comprehensive Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT06342908 is a Phase 1 study of Diffuse Hemispheric Glioma, H3 G34-Mutant that is active but no longer recruiting, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 6 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06342908, a Phase 1 study of Diffuse Hemispheric Glioma, H3 G34-Mutant, is active but no longer recruiting, sponsored by Jonsson Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial tests the safety and side effects, and best dose of a vaccine (neoantigen-target ppDC) in treating patients with H3 G34-mutant diffuse hemispheric glioma. Vaccines made from the patient's own white blood cells and peptide-pulsed dendritic cells may help the body build an effective immune response to kill tumor cells. Giving neoantigen-targeted ppDC may be safe, tolerable and/or effective in treating patients with diffuse hemispheric glioma with a H3 G34 mutation.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Leukapheresis
- DRUG Poly ICLC
- BIOLOGICAL Dendritic Cell Therapy
Study Locations (1)
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2024-06-14 |
| Est. Completion | 2028-01-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06342908
The ClinicalTrials.gov registry entry for NCT06342908 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diffuse Hemispheric Glioma, H3 G34-Mutant appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06342908 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06342908 about?
NCT06342908 is a clinical study titled "A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma". This phase I trial tests the safety and side effects, and best dose of a vaccine (neoantigen-target ppDC) in treating patients with H3 G34-mutant diffuse hemispheric glioma. Vaccines made from the patient's own white blood cells and peptide-pulsed dendritic cells may help the body build an effective...
What is the current status of trial NCT06342908?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2024-06-14. Estimated completion is 2028-01-09.
What conditions does trial NCT06342908 study?
This clinical trial studies the following conditions: Diffuse Hemispheric Glioma, H3 G34-Mutant.
What interventions are being tested in trial NCT06342908?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Leukapheresis (PROCEDURE), Poly ICLC (DRUG), Dendritic Cell Therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT06342908?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06342908 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Hemispheric Glioma, H3 G34-Mutant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.